Bio-Gene Technology confirms US patent for use of flavesone

Latest News

Agtech company Bio-Gene Technology (ASX:BGT) has announced the allowance of a patent application (17/045,457) by the United States Patent Office.

In May 2020, the company submitted Bio-Gene submitted an international patent application designating key countries around the world, including the US, designed to extend the protection of its technology for use as insecticides.

The company said the patent application focused on Flavocide for control of aphid pests.

The US Patent Office has now issued a Notice of Allowance to grant a patent containing the claims of US patent application relating to the use of flavesone and related molecules to control important aphid pest species on plants, including the Green peach aphid and the Russian wheat aphid.

The patent is expected to expire in May 2040.

Examination of additional patent applications relating to control of aphid pests is continuing by other patent offices in countries around the world, said the company.

Bio-Gene CEO Richard Jagger said, “We are extremely pleased with the allowance of this US patent application as the USA is a large target market for our products. Patent protection in this important market creates significant value for Bio-Gene and our commercial partners. We are continuing to develop commercial applications for our products in both crop and non-crop markets and patent protection is critical to commercialising our technology. This allowance further strengthens our intellectual property and validates our commitment to cutting-edge solutions that deliver innovation in the field of crop protection.”